Transforming growth factor beta 1 induction is associated with transforming growth factors beta 2 and beta 3 down-modulation in 12-O-tetradecanoylphorbol-13-acetate-induced skin hyperplasia

Cancer Res. 1993 Nov 15;53(22):5517-22.

Abstract

Acute treatment of mouse skin with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) induces marked epidermal hyperplasia, which is well evident by 24 h and maximal by 48-72 h. These effects are associated with the early induction of transforming growth factor (TGF) beta 1 expression in the epidermis. We show here that, in contrast to TGF-beta 1, TGF-beta 2, and TGF-beta 3, skin expression is significantly down-modulated in response to TPA. TGF-beta 3 RNA levels decreased by 6 h of treatment but returned to normal or even higher levels at later times. The TGF-beta 3 protein could be detected immunohistochemically in both dermis and epidermis in control skins and at early times of TPA treatment. However, at later times, TGF-beta 3 was found only in dermal cells and not in the epidermis. TGF-beta 2 RNA expression was found to be significantly down-modulated by 24 h of TPA treatment and remained low even at later times. Thus, differential control of the 3 TGF-beta isoforms appears to be a likely determinant of normal skin homeostasis and could be at least partially responsible for TPA-induced skin hyperplasia.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Down-Regulation*
  • Female
  • Hyperplasia / chemically induced
  • Hyperplasia / metabolism
  • Mice
  • RNA / analysis
  • Skin / drug effects
  • Skin / metabolism
  • Skin / pathology*
  • Tetradecanoylphorbol Acetate
  • Transforming Growth Factor beta / analysis
  • Transforming Growth Factor beta / biosynthesis*

Substances

  • Transforming Growth Factor beta
  • RNA
  • Tetradecanoylphorbol Acetate